| pubmed-article:1666181 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C0006100 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C1551080 | lld:lifeskim |
| pubmed-article:1666181 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:1666181 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1666181 | pubmed:dateCreated | 1992-4-21 | lld:pubmed |
| pubmed-article:1666181 | pubmed:abstractText | We report the synthesis and molecular characterization of a biotinylated analog of kallidin, [Lys]bradykinin. Bradykinin was prepared by solid phase peptide synthesis. Before cleavage from the resin, a biotin moiety was coupled to the epsilon amino group of a lysine in the zeroth position of the bradykinin peptide. An omega-amino caproic acid spacer was incorporated between the biotin group and the N-terminal lysine. The biotinylated peptide was deprotected, cleaved from the resin and purified by RP-HPLC. The identity of this analog was confirmed by amino acid analysis and FAB-mass spectrometry. Biotinyl [Lys]bradykinin (BLBK, mol, wt. = 1528) inhibited [3H]-bradykinin binding to guinea pig ileum homogenates dose dependently, with an IC50 of 28.9 +/- 6 nM. The IC50 for [Lys]bradykinin was approximately 10-fold lower, 3.2 +/- 0.6 nM. BLBK induced contractility in an isolated guinea pig smooth muscle preparation with an EC50 of 129 +/- 14 nM; the corresponding value for [Lys]bradykinin was 29 +/- 8 nM. These data are consistent with the difference in binding potency observed for BLBK compared to [Lys]bradykinin. In an ELISA assay using BLBK and affinity-purified rabbit anti-bradykinin antibody, BLBK bound to anti-bradykinin antibody with an EC50 = 1.21 +/- 0.54 nM. Rank order potencies for several bradykinin peptide analogs suggest that the epitope on bradykinin recognized by the antibody is likely to be at the carboxy terminus of the peptide. | lld:pubmed |
| pubmed-article:1666181 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1666181 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1666181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1666181 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1666181 | pubmed:issn | 0196-9781 | lld:pubmed |
| pubmed-article:1666181 | pubmed:author | pubmed-author:KellerDD | lld:pubmed |
| pubmed-article:1666181 | pubmed:author | pubmed-author:WolfeHH | lld:pubmed |
| pubmed-article:1666181 | pubmed:author | pubmed-author:SawutzD GDG | lld:pubmed |
| pubmed-article:1666181 | pubmed:author | pubmed-author:YanniJJ | lld:pubmed |
| pubmed-article:1666181 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1666181 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:1666181 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1666181 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1666181 | pubmed:pagination | 1019-24 | lld:pubmed |
| pubmed-article:1666181 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:meshHeading | pubmed-meshheading:1666181-... | lld:pubmed |
| pubmed-article:1666181 | pubmed:articleTitle | Synthesis and molecular characterization of a biotinylated analog of [Lys]bradykinin. | lld:pubmed |
| pubmed-article:1666181 | pubmed:affiliation | Department of Enzymology and Receptor Biochemistry, Sterling Research Group, Sterling Drug Inc., Malvern, PA 19355. | lld:pubmed |
| pubmed-article:1666181 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1666181 | pubmed:publicationType | In Vitro | lld:pubmed |
